Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluphenazine Hydrochloride

FDA-approved product (injectable, injection), marketed as Fluphenazine Hydrochloride, Permitil, Prolixin.

Registered studies
5
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Fluphenazine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Mental or behavioural disorder
  • Psychosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phenothiazines with piperazine structure
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis77.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

5registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluphenazine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluphenazine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacovigilance in Gerontopsychiatric Patients

    NCT02374567 · start 2015-01

    Registered record
    Registry ID
    NCT02374567
    Conditions
    Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
    Interventions
    Phenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine; Valproic Acid; Lamotrigine; Topiramate; Gabapentin; Levetiracetam; Pregabalin; Lacosamide; Clonazepam; Biperiden; Levomepromazine; Fluphenazine; Perphenazine; Perazine; Thioridazine; Haloperidol; Melperone; Pipamperone; Bromperidol; Benperidol; Sertindole; Ziprasidone; Flupentixol; Chlorprothixene; Zuclopenthixol; Fluspirilene; Pimozide; Clozapine; Olanzapine; Quetiapine; Sulpiride; Tiapride; Amisulpride; Prothipendyl; Risperidone; Aripiprazole; Paliperidone; Diazepam; Oxazepam; Lorazepam; Bromazepam; Clobazam; Alprazolam; Hydroxyzine; Buspirone; Chloral Hydrate; Flurazepam; Nitrazepam; Triazolam; Lormetazepam; Temazepam; Midazolam; Brotizolam; Zopiclone; Zolpidem; Zaleplon; Melatonin; Clomethiazole; Diphenhydramine; Promethazine; Imipramine; Clomipramine; Opipramol; Trimipramine; Amitriptyline; Nortriptyline; Doxepin; Maprotiline; Amitriptyline oxide; Fluoxetine; Citalopram; Paroxetine; Sertraline; Fluvoxamine; Escitalopram; Tran
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2017-06-28
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Depression; Schizophrenia; Psychosomatic Disorders +1 more
    InterventionPhenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine +75 more
    PhasePhase 3
    Registry statusTerminated

  • Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

    NCT01323205 · start 2011-05

    Registered record
    Registry ID
    NCT01323205
    Conditions
    Schizophrenia
    Interventions
    JNJ-40411813; JNJ-40411813; Placebo; Antipsychotic medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionJNJ-40411813; JNJ-40411813; Placebo; Antipsychotic medication
    PhasePhase 2
    Registry statusCompleted

  • Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

    NCT00821301 · start 2008-12

    Registered record
    Registry ID
    NCT00821301
    Conditions
    Multiple Myeloma
    Interventions
    Fluphenazine HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2008-12
    Completion
    2010-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionFluphenazine HCl
    PhasePhase 1
    Registry statusUnknown

  • Fluphenazine Hydrochloride for Psoriasis

    NCT00929578 · start 2008-11

    Registered record
    Registry ID
    NCT00929578
    Conditions
    Psoriasis
    Interventions
    Fluphenazine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11
    Completion
    2011-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionFluphenazine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma

    NCT00335647 · start 2006-01

    Registered record
    Registry ID
    NCT00335647
    Conditions
    Multiple Myeloma and Plasma Cell Neoplasm
    Interventions
    fluphenazine hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2006-01
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma and Plasma Cell Neoplasm
    Interventionfluphenazine hydrochloride
    PhasePhase 1 / Phase 2
    Registry statusCompleted